GlassScriptPhysician profile
Harold Avella
NPI 1770502965
$1,204.75
in general payments reported to CMS, 2019-2025
10 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $48.77 · 2021: $205 · 2022: $125 · 2023: $71.27 · 2024: $368 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $846.12 | 2019-2025 | Ztlido |
| Daiichi Sankyo INC. | $142.26 | 2019 | |
| Valinor Pharma, LLC | $57.60 | 2024-2025 | Movantik |
| Grt US Holding, INC. | $42.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.18 | 2019-2020 | |
| Forte Bio-Pharma LLC | $23.21 | 2021 | |
| Protega Pharmaceutials INC | $18.89 | 2025 | Roxybond |
| Ibsa Pharma INC. | $16.67 | 2021 | |
| Zyla Life Sciences, INC. | $16.34 | 2019 | |
| Horizon Therapeutics Plc | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Avella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.